These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 30613407)

  • 1. Effect of ranolazine on glycaemia in adults with and without diabetes: a meta-analysis of randomised controlled trials.
    Teoh IH; Banerjee M
    Open Heart; 2018; 5(2):e000706. PubMed ID: 30613407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.
    Fanaroff AC; James SK; Weisz G; Prather K; Anstrom KJ; Mark DB; Ben-Yehuda O; Alexander KP; Stone GW; Ohman EM
    J Am Coll Cardiol; 2017 May; 69(18):2304-2313. PubMed ID: 28473136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
    Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome.
    Chisholm JW; Goldfine AB; Dhalla AK; Braunwald E; Morrow DA; Karwatowska-Prokopczuk E; Belardinelli L
    Diabetes Care; 2010 Jun; 33(6):1163-8. PubMed ID: 20357382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ranolazine and trimetazidine on glycemic status in diabetic patients with coronary artery disease - a randomized controlled trial.
    Sandhiya S; Dkhar SA; Pillai AA; George M; Jayaraman B; Chandrasekaran A
    J Clin Diagn Res; 2015 Jan; 9(1):OC01-5. PubMed ID: 25738014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Ranolazine in Diabetic Patients: A Systematic Review and Meta-analysis.
    Zeng X; Zhang Y; Lin J; Zheng H; Peng J; Huang W
    Ann Pharmacother; 2017 Dec; ():1060028017747901. PubMed ID: 29231052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
    Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression.
    Baumeister H; Hutter N; Bengel J
    Cochrane Database Syst Rev; 2012 Dec; 12():CD008381. PubMed ID: 23235661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
    Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
    JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
    Sabatine MS; Leiter LA; Wiviott SD; Giugliano RP; Deedwania P; De Ferrari GM; Murphy SA; Kuder JF; Gouni-Berthold I; Lewis BS; Handelsman Y; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR
    Lancet Diabetes Endocrinol; 2017 Dec; 5(12):941-950. PubMed ID: 28927706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial.
    Frías JP; Nakhle S; Ruggles JA; Zhuplatov S; Klein E; Zhou R; Strange P
    Diabetes Obes Metab; 2017 Jan; 19(1):40-48. PubMed ID: 27527911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
    Weisz G; Généreux P; Iñiguez A; Zurakowski A; Shechter M; Alexander KP; Dressler O; Osmukhina A; James S; Ohman EM; Ben-Yehuda O; Farzaneh-Far R; Stone GW;
    Lancet; 2016 Jan; 387(10014):136-45. PubMed ID: 26474810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.
    Zhu H; Xu X; Fang X; Zheng J; Zhao Q; Chen T; Huang J
    Clin Ther; 2019 Oct; 41(10):2137-2152.e12. PubMed ID: 31548105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
    Chaitman BR
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
    Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
    J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials.
    Banon D; Filion KB; Budlovsky T; Franck C; Eisenberg MJ
    Am J Cardiol; 2014 Mar; 113(6):1075-82. PubMed ID: 24462341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.
    Nicolucci A; Ceriello A; Di Bartolo P; Corcos A; Orsini Federici M
    Diabetes Ther; 2020 Mar; 11(3):573-584. PubMed ID: 31873857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.